Vacunación en poblaciones especiales en épocas de COVID-19
The creation of the Immunization Program, has been one of the strategies with the greatest impact on public health. Vaccination would prevent 69 million deaths in poor countries. Influenza and pneumococcal disease cause a higher prevalence of complications in adults with comorbidit...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/38996 |
| Aporte de: |
| id |
I10-R327-article-38996 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
vaccination adults comorbidities vacunación adultos comorbilidades |
| spellingShingle |
vaccination adults comorbidities vacunación adultos comorbilidades Martinez Benavidez, CE Villarreal, G Ordoñez, MA Tolosa, MV Vacunación en poblaciones especiales en épocas de COVID-19 |
| topic_facet |
vaccination adults comorbidities vacunación adultos comorbilidades |
| author |
Martinez Benavidez, CE Villarreal, G Ordoñez, MA Tolosa, MV |
| author_facet |
Martinez Benavidez, CE Villarreal, G Ordoñez, MA Tolosa, MV |
| author_sort |
Martinez Benavidez, CE |
| title |
Vacunación en poblaciones especiales en épocas de COVID-19 |
| title_short |
Vacunación en poblaciones especiales en épocas de COVID-19 |
| title_full |
Vacunación en poblaciones especiales en épocas de COVID-19 |
| title_fullStr |
Vacunación en poblaciones especiales en épocas de COVID-19 |
| title_full_unstemmed |
Vacunación en poblaciones especiales en épocas de COVID-19 |
| title_sort |
vacunación en poblaciones especiales en épocas de covid-19 |
| description |
The creation of the Immunization Program, has been one of the strategies with the greatest impact on public health. Vaccination would prevent 69 million deaths in poor countries. Influenza and pneumococcal disease cause a higher prevalence of complications in adults with comorbidities such as diabetes, respiratory and rheumatic diseases. Vaccination against predisposing diseases has a beneficial impact on the prevention of mortality, morbidity and disability due to immunopreventable diseases, even so, the prevalence of these diseases continues to be high. The aim of this study is to know what percentage of patients, who due to special situations are included in the high-risk group, have vaccination against; influenza, PCV13, PPSV23 and COVID-19, to discriminate by vaccine, to know the relationship between vaccination and COVID-19 infection and to know the reasons why this population is not vaccinated.
The study included patients over 18 years of age with diabetes 2, autoimmune connective tissue diseases, chronic kidney disease, coronary heart disease, asthma, COPD, and hypertension, who attended Misericordia Hospital from March to September 2021. The vaccination card data recorded in the medical record were reviewed for all patients.
There were 49 patients, 16 men and 33 women, average age 47 years, 40% were hypertensive, 57% were asthmatic, 4% had heart disease, 40% were diabetic, 5% had chronic kidney disease and 7% had autoimmune connective tissue diseases. When discriminated by type of vaccine, the great majority had been vaccinated against influenza and the first dose against SARS-COVS 2. Only 56% of the patients had the complete vaccination schedule. 30% reported having been infected with COVID 19 and only one of those who became ill was vaccinated with the complete vaccination schedule. One person refused vaccination, citing fear.
The percentage of high-risk patients fully vaccinated in our work is low, being the Influenza vaccine the one they adhere to the most. People with a full schedule of vaccination against COVID-19 had less infection. The number of people immunized against pneumococcus could be underestimated, because its indication is for patients with moderate or severe asthma. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/38996 |
| work_keys_str_mv |
AT martinezbenavidezce vacunacionenpoblacionesespecialesenepocasdecovid19 AT villarrealg vacunacionenpoblacionesespecialesenepocasdecovid19 AT ordonezma vacunacionenpoblacionesespecialesenepocasdecovid19 AT tolosamv vacunacionenpoblacionesespecialesenepocasdecovid19 |
| first_indexed |
2024-09-03T21:03:54Z |
| last_indexed |
2024-09-03T21:03:54Z |
| _version_ |
1809210340678828032 |
| spelling |
I10-R327-article-389962024-04-15T16:14:45Z Vacunación en poblaciones especiales en épocas de COVID-19 Martinez Benavidez, CE Villarreal, G Ordoñez, MA Tolosa, MV vaccination adults comorbidities vacunación adultos comorbilidades The creation of the Immunization Program, has been one of the strategies with the greatest impact on public health. Vaccination would prevent 69 million deaths in poor countries. Influenza and pneumococcal disease cause a higher prevalence of complications in adults with comorbidities such as diabetes, respiratory and rheumatic diseases. Vaccination against predisposing diseases has a beneficial impact on the prevention of mortality, morbidity and disability due to immunopreventable diseases, even so, the prevalence of these diseases continues to be high. The aim of this study is to know what percentage of patients, who due to special situations are included in the high-risk group, have vaccination against; influenza, PCV13, PPSV23 and COVID-19, to discriminate by vaccine, to know the relationship between vaccination and COVID-19 infection and to know the reasons why this population is not vaccinated. The study included patients over 18 years of age with diabetes 2, autoimmune connective tissue diseases, chronic kidney disease, coronary heart disease, asthma, COPD, and hypertension, who attended Misericordia Hospital from March to September 2021. The vaccination card data recorded in the medical record were reviewed for all patients. There were 49 patients, 16 men and 33 women, average age 47 years, 40% were hypertensive, 57% were asthmatic, 4% had heart disease, 40% were diabetic, 5% had chronic kidney disease and 7% had autoimmune connective tissue diseases. When discriminated by type of vaccine, the great majority had been vaccinated against influenza and the first dose against SARS-COVS 2. Only 56% of the patients had the complete vaccination schedule. 30% reported having been infected with COVID 19 and only one of those who became ill was vaccinated with the complete vaccination schedule. One person refused vaccination, citing fear. The percentage of high-risk patients fully vaccinated in our work is low, being the Influenza vaccine the one they adhere to the most. People with a full schedule of vaccination against COVID-19 had less infection. The number of people immunized against pneumococcus could be underestimated, because its indication is for patients with moderate or severe asthma. La creación del Programa de Inmunizaciones, ha sido una de las estrategias con mayor impacto en la salud pública. La vacunación evitaría 69 millones de muertes en países pobres. La Influenza y la enfermedad neumocócica, provocan mayor prevalencia de complicaciones en adultos con comorbilidades como la diabetes, las enfermedades respiratorias y reumáticas. La vacunación contra enfermedades predisponentes, tiene un impacto beneficioso en la prevención de la mortalidad, morbilidad y discapacidad por enfermedades inmunoprevenibles, aún así, la prevalencia de estas enfermedades continúa siendo elevada. El objetivo de este trabajo es conocer qué porcentaje de pacientes, que por situaciones especiales se incluyen en el grupo de alto riesgo, tienen el esquema de vacunación antigripal, Prevenar 13, Pneumo 23 y contra COVID-19 completas, discriminar por vacuna, conocer la relación entre vacunación e infección por COVID-19 y conocer las causas por las que esta población no está vacunada. Se incluyeron mayores de 18 años con diabetes 2, enfermedades autoinmunes del tejido conectivo, enfermedad renal crónica, coronaria, asma, EPOC e hipertensión arterial, que concurrieron al hospital Misericordia desde marzo a septiembre de 2021. A todos se les revisaron los datos del carnet de vacunación registrados en la historia clínica. Se incorporaron 49 personas, 16 varones y 33 mujeres, promedio de edad de 47 años, el 40% fueron hipertensos, 57% asmáticos, 4% cardiópatas, 40% diabéticos, 5% padecían de enfermedad renal crónica y 7% enfermedades autoinmunes del tejido conectivo. Al discriminar por tipo de vacuna, la gran mayoría tenía colocada antigripal y la primera dosis anti SARS-COVS 2. Sólo el 56 % de los pacientes tenía el esquema de vacunación completo. El 30% refirió haber presentado la infección por COVID 19 y sólo uno de los que enfermaron estaba vacunado con el esquema completo. Una persona, se negó a la vacunación, refiriendo miedo. El porcentaje de pacientes de alto riesgo vacunados en forma completa para en nuestro trabajo es bajo, siendo la vacuna de la Influenza a la que más adhieren. Las personas con esquema completo de vacunación contra COVID-19 tuvieron menos infección. El número de personas inmunizadas contra el neumococo podría estar subestimado, porque su indicación es para pacientes con asma moderada o grave. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-10-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto texto https://revistas.unc.edu.ar/index.php/med/article/view/38996 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. Suplemento JIC XXIII (2022): Suplemento JIC XXIII Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. Suplemento JIC XXIII (2022): Suplemento JIC XXIII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |